Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.66 |
| ▸ | CCR1 | P32246 | 1/20 | 0.65 |
| ▸ | CCR5 | P51681 | 1/20 | 0.65 |
| ▸ | CCR8 | P51685 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | LDHA | P00338 | 2/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28148510 | 0.98 | CYP3A4 (0.63) | CYP3A4CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL12359222 | 0.96 | CYP3A4 (0.61) | CYP3A4CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL15614084 | 0.94 | CYP3A4 (0.65) | CYP3A4CYP2A6CCR1CCR5CCR8 | |
| Pyridine SCHEMBL28163164 | 0.90 | CYP3A4 (0.71) | CYP3A4CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL27890976 | 0.90 | CYP3A4 (0.56) | CYP3A4CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL9974926 | 0.89 | CYP3A4 (0.54) | CYP3A4CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL17051514 | 0.88 | CCR1 (0.75) | CYP3A4CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL10057488 | 0.87 | CYP3A4 (0.53) | CYP3A4CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL2480995 | 0.86 | CYP3A4 (0.56) | CYP3A4CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL2477927 | 0.86 | CCR1 (0.71) | CYP3A4CYP2A6CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124770-A1 | COMPOUND, GUEST MATERIAL OF LIGHT-EMITTING LAYER, ORGANIC ELECTROLUMINESCENT DEVICE, AND DISPLAY DEVICE | BEIJING NORMAL UNIVERSITY (CN) | 2024-04-18 | — | — | US | claimed |
| WO-2022166889-A1 | COMPOUND, GUEST MATERIAL OF LIGHT-EMITTING LAYER, ORGANIC ELECTROLUMINESCENT DEVICE, AND DISPLAY DEVICE | 北京师范大学 | 2022-08-11 | — | — | WO | claimed |
| WO-2017046813-A1 | FLUORESCENT CYCLOMETALATED Ir (III) COMPLEXES AND FORMULATIONS/ COMPOSITIONS COMPRISING THE SAME | GUPTA PARNA (IN) | 2017-03-23 | — | — | WO | claimed |
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | claimed |
| CN-122011044-A | Organometallic compound and organic light-emitting layer material | 吉林奥来德光电材料股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-12439813-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPRATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12408242-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250250483-A1 | ORGANOMETALLIC COMPLEX AND LIGHT-EMITTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-08-07 | — | — | US | disclosed |
| EP-4570317-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2025-06-18 | — | — | EP | disclosed |
| CN-120118130-A | Organic metal compound and organic electroluminescent device comprising same | 吉林奥来德光电材料股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-120058810-A | Organic light-emitting doped material, preparation method thereof and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-5872136-A | Arylheteroaryl inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0891361-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036901-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0484857-B1 | Polyorganosiloxane having a quaternary salt at its one terminal and percutaneous absorption-promoting agent | SAGAMI CHEM RES (JP) | 1997-05-07 | — | — | EP | disclosed |
| US-5624680-A | SKIN ABSORPTION OF DRUGS WITH POLYETHERSILOXANE BLOCK COPOLYMERS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1997-04-29 | — | — | US | disclosed |
| EP-0710688-A1 | HYDROXYSILYL-TERMINATED POLYOXYETHYLENE COMPOUND, QUATERNARY-SALT-TERMINATED BLOCK COPOLYMER, AND PERCUTANEOUS ABSORPTION PROMOTER | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5200488-A | POLYORGANOSILOXANE HAVING A QUATERNARY SALT AT ITS ONE TERMINAL AND PERCUTANEOUS ABSORPTION-PROMOTING AGENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0484857-A2 | Polyorganosiloxane having a quaternary salt at its one terminal and percutaneous absorption-promoting agent | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12408242-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | CYP3A4 1215/4885CYP2A6 2971/4885CCR1 4248/4885 |
| US-12439813-B2 | Organic electroluminescent materials and devices | OCIAD2, DRD2, OPRD1 | CYP3A4 1872/4885CYP2A6 3103/4885CCR1 2902/4885 |
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | CYP3A4 1215/4885CYP2A6 2971/4885CCR1 4248/4885 |
| US-20250250483-A1 | ORGANOMETALLIC COMPLEX AND LIGHT-EMITTING DEVICE | CRY1, CRY2, RPS23 | CYP3A4 252/4885CYP2A6 1440/4885CCR1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.